Rate/rhythm control for atrial fibrillation and antithrombotic medication during the initiation phase and maintenance phase
| Initiation (n=310) | Maintenance (n=769) | |||
|---|---|---|---|---|
| Number of patients | Per cent | Number of patients | Per cent | |
| Rate/rhythm control treatment | ||||
| β-blocker | 143 | 46.1 | 369 | 48.0 |
| Sotalol* | 9 | 2.9 | 45 | 5.9 |
| Class 1c antiarrhythmic agent | 5 | 1.6 | 31 | 4.0 |
| Amiodarone | 15 | 4.8 | 63 | 8.2 |
| Rate-limiting calcium antagonist | 22 | 7.1 | 78 | 10.1 |
| Digoxin | 68 | 21.9 | 267 | 34.7 |
| No rate/rhythm medication | 97 | 31.3 | 154 | 20.0 |
| Antithrombotic medication | ||||
| Antiplatelet | 124 | 40.0 | 268 | 34.9 |
| Anticoagulant | 145 | 46.8 | 484 | 62.9 |
| Both antiplatelet and anticoagulant | 34 | 11.0 | 78 | 10.1 |
| Any antiplatelet and/or anticoagulant | 234 | 75.5 | 674 | 87.7 |
| No antithrombotic medication | 76 | 24.5 | 95 | 12.4 |
Totals of rows do not add up to the number of patients as patients may have received a combination and/or sequence of two or more treatments, that is, treatments are not mutually exclusive.
*Sotalol is a β-blocker with additional antiarrhythmic properties and so is shown separately from other β-blockers.